About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company's segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: AKBA
- Previous Close: $9.93
- 50 Day Moving Average: $9.95
- 200 Day Moving Average: $8.94
- 52-Week Range: $18,300,000.00 - $7.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.75
- P/E Growth: 0.00
- Market Cap: $181.90M
- Outstanding Shares: 18,300,000
- Beta: 1.07
- Return on Equity: -88.40%
- Return on Assets: -64.59%
Companies Related to Akebia Therapeutics:
- Current Ratio: 6.32%
- Quick Ratio: 6.32%
What is Akebia Therapeutics' stock symbol?
Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."
Where is Akebia Therapeutics' stock going? Where will Akebia Therapeutics' stock price be in 2017?
8 brokers have issued 12-month price targets for Akebia Therapeutics' shares. Their predictions range from $8.00 to $21.00. On average, they expect Akebia Therapeutics' stock price to reach $16.29 in the next twelve months.
When will Akebia Therapeutics announce their earnings?
Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
What are analysts saying about Akebia Therapeutics stock?
Here are some recent quotes from research analysts about Akebia Therapeutics stock:
- Aegis analysts commented, "Akebia announced that it had entered into a research and license agreement with Janssen Pharmaceuticals on February 9, 2017. The agreement grants Akebia an exclusive license for potential development and commercialization of hypoxia-inducible factor (HIF) prolyl hydroxylase-targeted compounds' In accordance with the agreement Akebia will pay Janssen an upfront cash payment of $1 mil within 30 days of execution of the agreement. Janssen is also eligible to receive up to an aggregate of $16.5 mil in specified development milestones on a product-byproduct basis. The agreement also specifies that Janssen is eligible to receive up to $215 mil in specified commercial milestones, in addition to tiered, escalating royalties in the range of low to mid-single digits as a percentage of net sales on a product-by-product basis." (2/14/2017)
According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (1/11/2017)
Brean Capital analysts commented, "We like Akebia's asset, vadadustat, which is a new MOA for treating anemia. If successfully developed, it could change the standard of care," analyst Difei Yang wrote in a note.Related Link: Sarepta Dosing First Patients In Phase 3 Trial Of Duchenne Muscular Dystrophy Drug"International partnerships aside, Akebia will commercialize vadadustat on its own in the US and we project sales to be around $515 mil in 2022, with sales for ND-CKD indication alone," (9/29/2016)
HC Wainwright analysts commented, "Trevena announced this morning that the Phase 2b trial of TRV027 in Acute Heart Failure (BLAST-AHF) failed to meet all primary and secondary endpoints. Investor expectations for a successful outcome were relatively low, especially given the historical challenges w/ developing a drug in this indication. We had a modest positive bias given prior preclinical and clinical data. We have removed TRV027 from our model and are lowering our price target to $11 (was $14; 25x 2021 EPS estimate discounted 25% annually). We do not believe the negative TRV027 outcome has an impact on other programs in development at the company. The stock is still undervalued in our opinion, especially given strength of oliceridine pain program and we reiterate BUY." (5/16/2016)
Who owns Akebia Therapeutics stock?
Akebia Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (5.09%), Acuta Capital Partners LLC (3.82%), Marshall Wace LLP (3.76%), Perceptive Advisors LLC (2.94%), State Street Corp (2.90%) and City Financial Investment Co Ltd (1.75%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas.
Who sold Akebia Therapeutics stock? Who is selling Akebia Therapeutics stock?
Akebia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Ellington Management Group LLC and Acuta Capital Partners LLC. Company insiders that have sold Akebia Therapeutics stock in the last year include Duane Nash, Michel Dahan and Nicole R Hadas.
Who bought Akebia Therapeutics stock? Who is buying Akebia Therapeutics stock?
Akebia Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, City Financial Investment Co Ltd, Marshall Wace LLP, Renaissance Technologies LLC, Trexquant Investment LP, State Street Corp, Dynamic Technology Lab Private Ltd and Dimensional Fund Advisors LP.
How do I buy Akebia Therapeutics stock?
Shares of Akebia Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Akebia Therapeutics stock cost?
One share of Akebia Therapeutics stock can currently be purchased for approximately $9.94.